Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLTNASDAQ:FBIONASDAQ:MTEMNASDAQ:RGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$0.40-1.5%$0.46$0.38▼$1.48$15.14M0.96170,353 shs83,352 shsFBIOFortress Biotech$1.56-3.4%$1.69$1.36▼$2.89$42.93M1.75357,583 shs138,827 shsMTEMMolecular Templates$0.00-50.0%$0.00$0.00▼$2.04$1K1.2268,602 shs520 shsRGLSRegulus Therapeutics$1.81-7.9%$1.32$0.83▼$2.90$118.91M1.421.10 million shs535,914 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics+4.70%-8.86%-9.21%-29.65%-71.36%FBIOFortress Biotech+4.55%-4.17%+5.92%-24.06%-16.58%MTEMMolecular Templates0.00%-50.00%-60.00%-98.46%-99.99%RGLSRegulus Therapeutics+12.00%+51.94%+55.56%+25.64%-27.94%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics3.6591 of 5 stars3.05.00.00.03.33.31.3FBIOFortress Biotech2.5108 of 5 stars3.51.00.00.02.53.30.6MTEMMolecular Templates1.0619 of 5 stars0.00.00.04.60.62.50.6RGLSRegulus Therapeutics3.1145 of 5 stars3.54.00.00.03.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.00Hold$1.13184.81% UpsideFBIOFortress Biotech 3.00Buy$21.001,250.48% UpsideMTEMMolecular Templates 0.00N/AN/AN/ARGLSRegulus Therapeutics 3.00Buy$12.75606.37% UpsideCurrent Analyst Ratings BreakdownLatest BOLT, RGLS, MTEM, and FBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.003/25/2025BOLTBolt BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.50 ➝ $1.253/17/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/14/2025RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/11/2025FBIOFortress BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $16.002/26/2025RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.97N/AN/A$2.97 per share0.13FBIOFortress Biotech$62.50M0.69N/AN/A$0.10 per share15.55MTEMMolecular Templates$23.48M0.00N/AN/A$0.78 per share0.00RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$69.20M-$1.66N/AN/AN/A-665.56%-69.46%-48.55%5/13/2025 (Estimated)FBIOFortress Biotech-$60.64M-$2.78N/AN/AN/A-84.53%N/A-34.93%5/13/2025 (Estimated)MTEMMolecular Templates-$8.12M-$2.70N/A∞N/A-61.35%-260.50%-46.90%4/3/2025 (Estimated)RGLSRegulus Therapeutics-$30.04M-$0.87N/AN/AN/AN/A-53.07%-48.58%5/8/2025 (Estimated)Latest BOLT, RGLS, MTEM, and FBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024FBIOFortress Biotech-$0.79-$0.26+$0.53-$0.26$16.30 million$15.12 million3/24/2025Q4 2024BOLTBolt Biotherapeutics-$0.38-$0.38N/A-$0.42$0.79 million$0.01 million3/20/2025Q4 2024RGLSRegulus Therapeutics-$0.20-$0.20N/A-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt Biotherapeutics$0.3691.14%N/AN/A N/AFBIOFortress BiotechN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.213.163.16FBIOFortress BiotechN/A1.231.06MTEMMolecular TemplatesN/A1.561.56RGLSRegulus TherapeuticsN/A14.1514.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%FBIOFortress Biotech96.51%MTEMMolecular Templates95.47%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics30.90%FBIOFortress Biotech33.40%MTEMMolecular Templates13.90%RGLSRegulus Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics9038.34 million26.45 millionNot OptionableFBIOFortress Biotech17027.61 million18.39 millionOptionableMTEMMolecular Templates2606.58 million5.67 millionNo DataRGLSRegulus Therapeutics3066.24 million62.65 millionOptionableBOLT, RGLS, MTEM, and FBIO HeadlinesRecent News About These CompaniesWhy Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 12.00%April 3 at 1:51 AM | aaii.comRegulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech SummitApril 2 at 8:00 AM | prnewswire.comRegulus Therapeutics Leads The Charge Among 3 Promising Penny StocksMarch 31 at 5:35 PM | uk.finance.yahoo.comRegulus upgraded to Overweight from Equal Weight at Wells FargoMarch 29, 2025 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)March 29, 2025 | markets.businessinsider.comRegulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by Wells Fargo & CompanyMarch 29, 2025 | americanbankingnews.comRegulus jumps after data update from early-stage trial for kidney disease therapyMarch 28, 2025 | msn.comRegulus Therapeutics (NASDAQ:RGLS) Rating Increased to Overweight at Wells Fargo & CompanyMarch 28, 2025 | marketbeat.comWells Fargo Upgrades Regulus Therapeutics (RGLS)March 28, 2025 | msn.comWhy Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 16.28%March 28, 2025 | aaii.comRegulus stock surges on positive trial resultsMarch 27, 2025 | za.investing.comRegulus shares surge on Wells Fargo upgrade, clinical updateMarch 27, 2025 | investing.comRegulus Therapeutics (RGLS) Announces Promising Phase 1b Trial ResultsMarch 27, 2025 | gurufocus.comRegulus jumps after data from early-stage trial for kidney disease therapy (update)March 27, 2025 | msn.comRegulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney DiseaseMarch 27, 2025 | benzinga.comRegulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)March 27, 2025 | prnewswire.com4 Best Stocks To Buy Under $5March 20, 2025 | 247wallst.comWhat Makes Regulus (RGLS) a New Buy StockMarch 19, 2025 | zacks.comRegulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comRegulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at Canaccord Genuity GroupMarch 18, 2025 | marketbeat.comPromising Developments and Strategic Positioning Drive Buy Rating for Regulus TherapeuticsMarch 17, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBOLT, RGLS, MTEM, and FBIO Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$0.40 -0.01 (-1.50%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Fortress Biotech NASDAQ:FBIO$1.56 -0.06 (-3.42%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Molecular Templates NASDAQ:MTEM$0.0001 0.00 (-50.00%) As of 09:30 AM EasternMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Regulus Therapeutics NASDAQ:RGLS$1.80 -0.16 (-7.91%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
